Who
Jennifer Kayden Lee
EVP, Head of North America
Company insider
Files Form 4 as: EVP, Head of North America, Rhythm Pharmaceuticals; Chief Commercial Officer, Krystal Biotech.
In numbers
- Trades disclosed
- 117
- Buys
- 0
- Sells
- 25
- Bought
- $0
- Sold
- $25.8M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 31 Jan 2020
- Last trade
- 13 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $850K35,000 at $24.29 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $147K21,601 at $6.80 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8.9M75,834 at $117.38 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,601 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,601 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $850K35,000 at $24.29 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $147K21,601 at $6.80 | filing |
| 13 Aug 2026filed 14 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8.9M75,834 at $117.38 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,650 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,650 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —22,612 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.0M9,237 at $108.99 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,437 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,437 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,512 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
News
Contrasting Rhythm Pharmaceuticals (NASDAQ:RYTM) & ADMA Biologics (NASDAQ:ADMA)RYTM · dailypolitical.com · 22 Oct 2026Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRYTM · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Jennifer Kayden Lee; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.